Could CannTrust Holdings (TSX:TRST) Stock Recover in 2020?

Here’s why bargain hunters should be placing contrarian bets on beaten-down cannabis stock CannTrust Holdings (TSX:TRST)(NYSE:CTST) today.

question marks written reminders tickets

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

A beleaguered CannTrust Holdings’s (TSX:TRST)(NYSE:CTST) stock remains heavily beaten down today, even as the company appears much closer to regaining its licences and has preserved cash flow during the period with suspended operating licences.

Shares traded around $1.20 exit 2019, and they had recorded an agonizing low of $0.99 a share recently — a price point too bearish, even after considering the self-inflicted crisis the company finds itself in today.

Let me explain.

Trading below cash value?

At a share price of $1.20 on Thursday, the company’s total market capitalization was a humble $169 million. Yet management disclosed that CannTrust had a cash balance of around $185 million on in its coffers as of November 30, 2019.

Barely a month later, investors had discounted this liquid resource by a significant margin, and written off all the company’s tangible assets. There isn’t any goodwill on TRST’s books. All tangible assets, including grow rooms and processing facilities, were essentially written off by the market.

You could theoretically buy the whole company for its cash resources and make a staggering profit just by winding up its operations and selling off property and plant and equipment assets at giveaway prices in a fire sale auction.

The company promised to temporarily lay off about 140 of its employees between October and December 31 to save about $0.4 million in cash flow per month, and the move will only cost about $0.8 million in severance packages if the individuals aren’t re-hired within 35 weeks. The cash balance could stretch for longer.

No debt in capital structure

There’s no debt on the company’s books after the last loan was paid off before maturity, so there aren’t any debts to worry about anymore.

And then the licences…

The company could potentially be back in compliance with Health Canada’s guidelines and regulatory requirements within three months from now.

Reading from a December 5, 2019, update, management could meet the conditions for the reinstatement of their suspended business licences by the end of the first quarter of 2020, but this will be subject to Health Canada input and approval.

As I argued earlier, the regulator has been very lenient with this once-rogue pot producer, and it was up to a serious executive team to bring the company back in good terms with the key stakeholder with an average effort.

News of licences reinstatement could violently lift the stock from today’s trading levels.

Potential risks

Several investor class-action lawsuits have been served or still in the process of being filed. There should be some strong evidence against the company if media reports that claimed that even the CEO was an accomplice in the scandal are to be taken seriously.

Lawsuits could drain all liquidity and sink the firm forever, but there could be some insurance cover against such operational risk eventualities, and some property could still be sold to cover these.

Further, the company is yet to file its restated financial statements for the year 2018 and subsequent quarterly instalments. The longer it takes for these required documents to be lodged with securities regulators, the higher the risk of shares being delisted from exchanges. Delisted stocks face very high discounts for lack of liquidity.

The further shares trade below US$1.00 on the New York Stock Exchange, the higher the risk of delisting from this prime market, but the company has over five months to be back in compliance with minimum price requirements there, and the share price may skyrocket upon news of licences reinstatement much sooner.

Keen eyes are on the suspended licences. Sales need to resume for the accumulated inventory to be liquidated and bring in cash flow to the business. The longer it takes for licences to be granted, the harder it will be to revive the business and directly compete with peers for customers in an increasingly oversupplied marijuana market.

Foolish bottom line

It will be a challenge for CannTrust to regain market confidence and trust from all key stakeholders after the scandal settles. Risks remain elevated and keep increasing with each additional week that sales licences remain suspended.

I would still hold a position and anticipate to cash in when the good news rolls in.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Brian Paradza has no position in any of the stocks mentioned. The Motley Fool recommends CannTrust Holdings and CannTrust Holdings Inc.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »